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ABSTRACT
Prostate cancer (PCa) is a major cause of morbidity and mortality. Until now the 
specific role of histone methyltransferases (HMTs) deregulated expression/activity 
in PCa is poorly understood. Herein we aimed to uncover the potential oncogenic role 
of PRMT6 in prostate carcinogenesis. PRMT6 overexpression was confirmed in PCa, 
at transcript and protein level. Stable PRMT6 knockdown in PC-3 cells attenuated 
malignant phenotype, increasing apoptosis and decreasing cell viability, migration 
and invasion. PRMT6 silencing was associated with decreased H3R2me2a levels 
and increased MLL and SMYD3 expression. PRMT6 silencing increased p21, p27 and 
CD44 and decreased MMP-9 expression and was associated with PI3K/AKT/mTOR 
downregulation and increased AR signaling pathway. In Sh-PRMT6 cells, AR restored 
expression might re-sensitized cells to androgen deprivation therapy, impacting in 
clinical management of castration-resistant PCa (CRPC). PRMT6 plays an oncogenic 
role in PCa and predicts for more clinically aggressive disease, constituting a potential 
target for patients with CRPC.
INTRODUCTION
Prostate cancer (PCa) is the second most common 
malignant neoplasm diagnosed in men and the sixth 
leading cause of cancer-related mortality worldwide [1]. 
Serum PSA screening for PCa remains controversial, 
leading to significant overdiagnosis and overtreatment 
[2]. Thus, new diagnostic and prognostic biomarkers are 
required to improve clinical management and therapeutic 
decision-making.
Deregulation of epigenetic mechanisms contributes 
to PCa development and progression [3]. Histone post-
translational modifications [PTMs] are involved in gene 
expression control, influencing chromatin compaction 
and signaling for several protein complexes. Abnormal 
expression of histone methyltransferases (HMTs), 
including Mixed-Lineage Leukemia 2 (MLL2), Mixed-
Lineage Leukemia 3 (MLL3), nuclear receptor binding 
SET domain protein 1 (NSD1) [4], enhancer of zeste 
homolog 2 (EZH2) [5] or SET and MYND domain 
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containing 3 (SMYD3) [6], was reported in PCa. 
Recently, in a small cohort of PCa patients, we evaluated 
the expression of 37 HMTs, including protein arginine 
methyltransferase 6 (PRMT6), which was overexpressed, 
eventually discriminating normal from tumorous prostate 
tissues [6]. PRMT6, a type I arginine methyltransferase, 
displays high affinity for R2 of H3, exclusively catalyzing 
H3R2 asymmetric di-methylation [7]. Because H3R2me2 
is a repressive mark, PRMT6 activity was associated 
with transcriptional silencing [7]. The precise functions 
of PRMT6, however, are not completely understood, 
although it has been associated with altered cell 
proliferation, cellular senescence, DNA repair and innate 
immunity [8-12]. Our main goal was to explore the 
role of PRMT6 deregulation in prostate carcinogenesis, 
characterize the putative oncogenic role and its potential 
clinical impact.
RESULTS
PRMT6 is overexpressed in PCa
Relevant clinical and histopathological data are 
depicted in Table 1. PCa and NPT age distributions did 
not significantly differ. PRMT6 was overexpressed in 
PCa compared to NPT (Figure 1A), but no statistically 
significant association between PRMT6 expression and 
standard clinicopathological parameters was found. In 
ROC curve analysis, using 0.265 expression level as 
empirical cut-off, PCa tissues were discriminated from 
NPT with 70.3% sensitivity, 93% specificity, 99.3% 
positive predictive value (PPV) and 93% negative 
predictive value (NPV), portraying a global accuracy of 
71.9% (Figure 1B).
Statistically significant increase of PRMT6 
immunoexpression from NPTs to PCa (Figure 1C and 
1D), as well as association between PRMT6 transcript 
and protein levels was depicted (Figure 1E) (p<0.001). 
Statistically significant differences in PRMT6 transcript 
levels were detected between immunoscores +1 vs. 
+2 and +1 vs. +3 (p<0.01 and p< 0.001, respectively). 
No association was found, however, between PRMT6 
immunoexpression and prognosis.
PRMT6 is overexpressed and carries prognostic 
information in TCGA PCa dataset
PRMT6 expression results were validated in a larger 
and independent dataset, i.e., mRNAseq expression data 
from PCa patients and matched normal samples deposited 
in TCGA. PRMT6 expression levels were significantly 
overexpressed in PCa compared to prostate normal tissues 
(p<0.0001, Supplementary Figure 1A). Likewise, no 
significant associations were found between PMRT6 levels 
and any of the standard clinicopathological parameters. In 
52 matched PCa and normal prostate samples, PMRT6 
was significantly overexpressed in 89% of the tumors 
(p<0.0001; Supplementary Figure 1B). Interestingly, 
higher PRMT6 expression levels were associated with 
shorter disease-free survival, both in univariate and 
multivariate analyses (p<0.027) (Supplementary Figure 2).
Knockdown of PRMT6 in PC-3 and LNCaP cell 
lines
LNCaP, 22RV1, PC-3 and DU145 cell lines 
expressed PRMT6, at variable levels (Figure 2A). 
The most highly expressing androgen-responsive 
and androgen-refractory cell lines (LNCaP and PC-3, 
respectively) were chosen for subsequent in vitro studies. 
Effective PRMT6 knockdown was achieved in selected 
cell lines and confirmed at mRNA and protein level 
(Figure 2B).
PRMT6 knockdown attenuates malignant 
phenotype in PC-3 but not LNCaP cells
Cell viability was evaluated at days 0, 1, 2, and 3. 
In Sh-PRMT6 LNCaP, increased cell viability at 24h and 
48h was observed. However, at 72h, cell viability was 
similar to Sh-Scramble (Figure 3A). Concerning PC-3, 
a significant decrease in cell viability was observed after 
PRMT6 knockdown, at 48h and 72h (Figure 3B). PRMT6 
knockdown increased apoptosis, both in LNCaP and PC-
3, but only reached statistical significance in the latter 
(Figure 3C and 3D). A significant decrease in migration 
ability was observed in Sh-PRMT6 PC-3 (Figure 3E) 
as well as a decrease in invasion capacity, although it 
did not reach statistical significance (Figure 3F). These 
results were confirmed at molecular level, as a significant 
decrease in MMP9 and an increase in CD44 expression 
was depicted upon PRMT6 silencing (Figure 3G).
PRMT6 knockdown associates with global 
H3R2me2a downregulation
Because PRMT6 knockdown induced phenotypic 
alterations in silenced PC-3 cells, we looked for alterations 
in specific histone marks it catalyzes [7] and a global 
H3R2me2a reduction was confirmed (Figure 4A). PRMT6 
methyltransferase activity in arginine 2 counteracts MLL 
complex activity on lysine 4, both in histone 3, which are 
mutually exclusive [7]. Therefore, we evaluated the impact 
of PRMT6 knockdown in H3K4 methyltransferases (MLL 
complex and SMYD3) global expression levels by qRT-
PCR, and found that both were significantly increased 
in PC-3 cells upon PRMT6 knockdown (Figure 4B). 
The impact of PRMT6 knockdown on MLL complex 
activity in vitro was tested through the evaluation of 
the differences in H3K4me3 expression in PC-3 cells. 
However, no significant alterations in expression were 
apparent (Figure 4C).
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Since PRMT6 activity was associated with a 
decrease in MYC-dependent genes transcription [7] we 
evaluated MYC transcript levels after PRMT6 silencing. 
Interestingly, qRT-PCR analysis depicted a significant 
increase in MYC mRNA levels (Figure 4D).
PRMT6 knockdown interferes with PCa cell 
senescence and PI3K/AKT/mTOR pathways
Seeking for genes regulated by PRMT6, we 
evaluated putative targets associated with cellular 
processes and pathways relevant in PCa. Firstly, cellular 
senescence was investigated, as this biological process has 
been previously associated with PRMT6 activity [11, 12]. 
In PC-3 Sh-PRMT6 cells, western blot analysis showed a 
substantial increase of p27 expression whilst p21 was only 
slightly increased (Figure 5A).
The PI3K/AKT/mTOR pathway, which is frequently 
deregulated in PCa [13] was also investigated. In PC-3 Sh-
PRMT6 cells, AKT, pAKT and mTOR protein expression 
was significantly decreased (Figure 5B), suggesting PI3K/
AKT/mTOR pathway downregulation associated with 
PRMT6 silencing.
PRMT6 knockdown increases AR expression in 
PCa cell lines
The AR pathway, which is critically involved in 
PCa initiation and progression, was examined. In PC-3 
cells, which have only residual AR expression, PRMT6 
knockdown led to AR upregulation, both at transcript and 
protein level. To confirm these results, PSA (a well-known 
downstream target of AR) expression was assessed, and 
an impressive increase in PSA protein levels was apparent 
in PC-3 Sh-PRMT6 cells (Figure 6A). PRMT6-silenced 
LNCaP cells displayed a significant increase in AR mRNA 
but just a slight increase at protein level (Figure 6B).
Moreover, to assess whether PRMT6 is directly 
related to AR, we stably overexpressed AR in PC-3 cells. 
AR overexpression in PC-3 cells, at 72h, significantly 
associated with increased cell viability and decreased 
apoptosis (Supplementary Figure 3).
DISCUSSION
Altered HMTs expression patterns have been 
implicated in prostate carcinogenesis and disease 
progression [4-6]. Following our previous observation 
of PRMT6 overexpression in PCa [6], we attempted to 
confirm its putative oncogenic role and potential clinical 
implications.
Globally, altered pattern of PRMT6 in PCa mimics 
that of SMYD3, another HMT which targets different 
aminoacidic residues [6]. Although no significant 
associations with standard clinicopathological parameters 
were depicted, either in our series or TCGA dataset, 
PRMT6 overexpression associated with shorter interval to 
biochemical recurrence, suggesting that it imparts a more 
aggressive phenotype. Interestingly, PRMT6 transcript 
and protein levels were globally concordant, although no 
significant differences were depicted between scores +2 
and +3. This is most likely due to the semi-quantitative 
Table 1: Clinical and pathological data of patients
NPT PCa
Number of cases, n 15 195
Age (Years)
 Median (range) 64 (45-80) 64 (49-75)
PSA Levels (ng/ml)
 Median (range) N.A. 8.24 (0-23)
Pathological Stage, n (%)
 pT2
N.A.
109 (56%)
 pT3a 67 (34%)
 pT3b 19 (10%)
Gleason Score, n (%)
 < 7
N.A.
66 (34%)
 = 7 115 (59%)
 > 7 14 (7%)
N.A., Not applicable.
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nature of immunohistochemical scoring, which may not 
be able to discriminate among subtle, yet biologically 
significant, differences in protein levels. Indeed, 
mRNA quantitation is more objective and may better 
discriminate tumors with different biological and clinical 
aggressiveness, as demonstrated for SMYD3 [6].
Whereas an attenuation of the malignant phenotype 
(decreased cell viability and increased apoptosis) was 
consistently observed in Sh-PRMT6 PC-3, no consistent 
effect was apparent for LNCaP. This might be related to 
AR regulating role of PRMT6. Because PRMT6 activity 
leads to AR downregulation, its silencing increases AR 
transcription. Thus, it is tempting to speculate whether 
Sh-PRMT6 LNCaP would have survival advantage (as 
verified at 72h) due to increased AR availability. Sh-
PRMT6 PC-3 also demonstrated impaired migration 
Figure 1: PRMT6 relative expression levels in prostate tissues. A. PRMT6 is overexpressed in PCa compared to NPTs; B. 
Performance of PRMT6 mRNA expression as a biomarker for PCa. ROC curve evaluating the ability of PRMT6 expression levels in 
discriminating PCa from normal prostate tissues; C. Illustrative images of PRMT6 immunostaining in NPT and PCa samples; D. Distribution 
of PRMT6 immunoexpression and of E. PRMT6 transcript levels in a series of prostate tissue samples (NPT and PCa), grouped according 
to PRMT6 immunostaining. ****p<0.0001 (Mann-Whitney U-test); (AUC, area under curve; CI, confidence interval).
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capacity, that was validated at molecular level through 
MMP-9 (which promotes neoplastic cell invasion and 
metastasis [14]) downregulation and CD44 (involved 
in cell signaling and cell-cell and cell-matrix adhesion 
[15]) upregulation. Decreased CD44 expression was 
reported in primary and metastatic PCa [16]. Moreover, 
CD44 downregulation has been associated with increased 
grade and pathological stage, predicting tumor relapse 
and biochemical recurrence [17]. Interestingly, decreased 
CD44 expression in PCa has been associated with aberrant 
promoter methylation [18].
As expected, decreased H3R2m2 levels upon 
PRMT6 knockdown were experimentally verified. 
Moreover, increased MLL complex expression was 
observed, although no significant differences in 
H3K4me3 (the histone mark catalyzed by MLL) levels 
were apparent, even with concurrent SMYD3 increased 
expression. Because several other enzymes (which we 
did not assess) also catalyze the H3K4me3 mark, it is 
plausible that variations in MLL and SMYD3 might not 
impact in H3K4me3 global levels, although gene-specific 
effects of those variations cannot be dismissed.
Surprisingly, PRMT6 silencing caused a significant 
increase in MYC mRNA levels. It should be recalled 
that PRMT6-mediated H3R2 dimethylation antagonizes 
the function of the MLL1 complex [7]. Accordingly, we 
showed that PRMT6 knockdown in PCa was associated 
with increased MLLs transcript levels. Importantly, 
PRMT6 can bind to a subset of MYC-dependent genes and 
catalyze dimethylation of R2 in histone H3 at the 5´end of 
target genes. Additionally, PRMT6 leads to transcriptional 
repression by inhibition of H3K4 trimethylation, whereas 
PRMT6 detachment from its target genes allows for H3K4 
trimethylation, entailing target genes’ active transcription 
[7]. Because MYC is a putative target gene of PRMT6, 
increased MYC expression is then to be expected 
following PRMT6 silencing.
The observed increase of p21 and p27 expression 
levels in Sh-PRMT6 PC-3 cells is in line with 
previous observations [10, 11], implying that PRMT6 
overexpression likely interferes with normal cellular 
senescence in PCa, facilitating neoplastic transformation. 
Remarkably, p27 plays an important role in prostate 
carcinogenesis as its expression decreases with increased 
tumor grade and stage, and p27 downregulation associates 
with poor prognosis [19]. Furthermore, a decrease in cell 
proliferation accompanied by increased cell death due 
to apoptosis upon induction of p27 expression has been 
reported in PC-3 cells [20], corroborating our phenotypic 
assays results.
Alterations in PI3K/AKT/mTOR pathway were 
reported in 42% and 100% of primary and metastatic PCa, 
respectively [21], which is in line with downregulation of 
AKT, phospho-AKT and mTOR upon PRMT6 silencing. 
Although phosphatases and tensin homolog (PTEN), a 
negative regulator of PI3K/AKT/mTOR pathway, loss of 
expression in PCa is a common explanation for increased 
activity of that signaling pathway [22, 23], PRMT6 
might further contribute to PI3K/AKT/mTOR activation. 
Importantly, both PTEN loss and AKT activation have 
Figure 2: A. PRMT6 expression in PCa cell lines at RNA (upper panel) and protein level (lower panel); B. The efficiency of PRMT6 
knockdown was confirmed at mRNA level, using qRT-PCR (upper panel), and at protein level, using Western-Blot (lower panel), in LNCaP 
and PC-3 cells. *p<0.05 (Mann-Whitney U-test).
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been associated with biochemical recurrence after radical 
prostatectomy [24, 25], as well as resistance to radiation 
[26] and chemotherapy [27].
AR signaling is critical for normal development, 
function and homeostasis of the prostate and its 
deregulation has been implicated in tumor initiation 
and progression [28]. Although primary PCa is mostly 
an androgen-responsive tumor, the castration-resistant 
phenotype (CRPC) eventually emerges [28], and 
several mechanisms have been implicated, including 
heterogeneous loss of AR expression and aberrant 
promoter methylation [29]. Additionally, AR loss of 
expression associates with increased invasiveness [30]. 
PC-3 cells express AR at very low levels and might be, 
thus, considered a good model of CRPC. Remarkably, we 
found that PRMT6 silencing in PC-3 cells was associated 
Figure 3: Impact of PRMT6 knockdown in: A. LNCaP and B. PC-3 cell viability by MTT assay at 0h, 24h, 48h and 72h; C. LNCaP 
and D. PC-3 apoptosis by APOPercentage in Sh-Scramble at 72h in Sh-Scramble and Sh-PRMT6; E. PC-3 migration by woundhealing 
scratch assay, representing the upper panel the migration rate at 12h and 16h, and the lower panel illustrative images at the beginning and 
endpoint of the assay; F. PC-3 invasion by matrigel invasion assay, representing the upper panel the percentage of invasive cells at 24h 
and the lower panel illustrative images at the endpoint of the assay (24h); expression of G. CD44 and H. MMP9 by qRT-PCR in PC-3 Sh-
Scramble and Sh-PRMT6. *p<0.05, ***p<0.001 (Mann-Whitney U-test).
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Figure 6: AR expression in A. PC-3 PRMT6 silenced cells; qRT-PCR analysis of AR transcript levels (left panel) and western blot 
analysis of AR and PSA protein levels in PC-3 cell line (right panel) demonstrating that both AR and PSA are overexpressed after PRMT6 
silencing; B. LNCaP PRMT6 silenced cells both at transcript (left panel) and protein level (right panel). *p<0.05 (Mann-Whitney U-test).
Figure 4: A. Reduction of asymmetrical dimethylation of arginine 2 of histone 3 after PRMT6 knockdown in PC-3 cell line; B. Relative 
expression of methyltransferases that catalyze H3K4me3 in PC3 PRMT6-silenced cells namely MLL complex genes and SMYD3; C. 
Western blot analysis of H3K4me3 expression after PRMT6 knockdown in PC-3 cells; D. MYC transcript levels in PC-3 PRMT6 silenced 
cells. *p<0.05 (Mann-Whitney U-test).
Figure 5: Western blot analysis of A. p21 and p27 expression in PC-3 cell line after PRMT6 knockdown; B. AKT, pAKT and mTOR 
expression in PC-3 cell line after PRMT6 knockdown.
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with functionally restored AR expression, demonstrated 
by increased PSA expression. Moreover, AR upregulation 
might also contribute to decreased migration documented 
in Sh-PRMT6 PC-3 cells. Interestingly, strategies that 
restore AR expression and, thus, overcome CRPC, might 
be of clinical utility. However, AR induced expression in 
PC-3 cells did not show the same effect in viability and 
apoptosis as PMRT6 knockdown. This might be due to 
the previously reported opposed roles of AR expression in 
PCa cell lines [31]. Nevertheless, PRMT6 downregulation 
and/or inhibition might provide an innovative therapeutic 
strategy for CRPC, through restoration of AR expression, 
re-sensitizing neoplastic cells to androgen-deprivation 
therapy (ADT).
In summary, PRMT6 overexpression, at transcript 
and protein level, associated with worse disease-free 
survival in PCa, is suggestive of an oncogenic role. Stable 
PRMT6 knockdown attenuates the malignant phenotype 
in PC-3 but not LNCaP, probably due different baseline 
AR expression. At molecular level, PRMT6 silencing 
associates with decreased H3R2me2a levels and increased 
MLL complex and SMYD3 expression, and affects 
several key genes/molecules, involved in critical cellular 
pathways. Finally, restored AR expression in Sh-PRMT6 
PC-3 is of potential clinical relevance, suggesting that 
PRMT6 inhibition may re-sensitize androgen-insensitive 
neoplastic cells to ADT, providing a novel approach to 
CRPC management.
MATERIALS AND METHODS
Patients and samples
PCa samples (n=195) from patients diagnosed and 
primarily treated with radical prostatectomy at Portuguese 
Oncology Institute – Porto, Portugal were prospectively 
collected. Fifteen normal prostate tissue (NPT) samples, 
of peripheral zone of prostates without PCa, from patients 
submitted to radical cystoprostatectomy for bladder 
cancer, served as controls. All specimens, promptly 
frozen at -80ºC, were cut for nucleic acid extraction. For 
routine histopathological examination, formalin-fixed and 
paraffin-embedded (FFPE) fragments were also collected. 
Relevant clinical data was retrieved from clinical charts. 
This study was approved by the institutional review board 
(IRB-CES-IPOFG-EPE 215/013).
Immunohistochemistry
PRMT6 expression was assessed by 
immunohistochemistry in FFPE sections using the 
anti-PRMT6 mouse monoclonal antibody (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA) at 1:150 dilution 
with Novolink™ Polymer Detection System (Leica 
Biosystems, Germany). Normal testis served as positive 
control. PRMT6 immunoexpression was scored as +1 
(weak expression ≤ 50% of cells), +2 (weak expression 
> 50% of cells or moderate expression ≤ 50% of cells), 
+3 (moderate expression in > 50% of cells or intense 
expression, typically >50% of cells).
TCGA data in prostate cancer patients
Data on PRMT6 mRNA expression and clinical 
information (when available) from PCa and matched 
normal patient samples, deposited in The Cancer Genome 
Atlas (TCGA) was retrieved. mRNA expression data 
from samples hybridized at University of North Carolina, 
Lineberger Comprehensive Cancer Center, using 
Illumina HiSeq 2000 mRNA Sequencing version 2, were 
downloaded from TCGA data matrix (http://tcga-data.nci.
nih.gov/tcga/tcgaDownload.jsp), including 497 PCa and 
52 matched normal samples [32]. To prevent duplicates, 
when there was more than one portion per patient, median 
values were used. The provided value was pre-processed 
and normalized according to “level 3” specifications of 
TCGA (see https://gdc-portal.nci.nih.gov/ for details). 
Clinical data of each patient was provided by Biospecimen 
Core Resources (BCRs). Data is available for download 
through TCGA data matrix (http://tcga-data.nci.nih.gov/
tcga/dataAccessMatrix.htm).
PCa cell lines
PCa cell lines LNCaP, 22RV1, DU145 and PC-3 
were used for in vitro studies. LNCaP and 22Rv1 cells 
were grown in RPMI 1640, whereas DU145 and PC-3 
cells were maintained in MEM and 50% RPMI-50% 
F-12 medium (GIBCO, Invitrogen, Carlsbad, CA, USA), 
respectively. All basal culture media were supplemented 
with 10% fetal bovine serum and 1% penicillin/
streptomycin (GIBCO, Invitrogen, Carlsbad, CA, USA). 
Cells were maintained in an incubator at 37ºC with 5% 
CO2. All cell lines were G-banding karyotyped (for 
validation) and routinely tested for Mycoplasma spp. 
contamination (PCR Mycoplasma Detection Set, Clontech 
Laboratories).
Generation of sh-PRMT6 silenced cell lines
PRMT6 knockdown was achieved through viral 
transduction, in LNCaP and PC3 cell lines, using 
MISSION® shRNA Lentiviral Transduction Particles 
(SHCLNV_TRCN0000299934 and SHCLNV_
TRCN0000299933 for LNCaP and PC-3, respectively; 
Sigma-Aldrich®) in the presence of polybrene (Santa 
Cruz Biotechnology Inc.). Control LNCaP and PC3 
were generated using MISSION® Non-Mammalian 
shRNA Control Transduction Particles (SHC002V; 
Sigma-Aldrich®). After transduction, stable clones with 
shRNA were selected with Puromycin dihydrochloride 
(cat. 631306, Clontech Laboratories Inc.) at a final 
concentration of 3μg/mL or 5μg/mL in LNCaP or PC3 
cells, respectively.
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Androgen receptor overexpression
Androgen receptor or control-expressing PC3 
cells were generated by cloning AR into the pEZ-Lv105 
(Genecopoeia, Rockville, MD, USA). As a control, we 
used the same vector, but lacking an open reading frame. 
After confirmation of the insert sequence, Fugene 6 
transfection reagent (Promega, Madison, WI, USA) was 
applied to transfect the plasmid DNA into PC3 cells. 
Stably-transfected cells were selected using Puromycin 
(Clontech, Mountain View, CA, USA).
Real time quantitative PCR (qRT-PCR)
RNA was extracted from cell lines using TRIzol® 
(Invitrogen, Carlsbad, CA, USA). High-capacity cDNA 
Reverse Transcription Kit from Applied Biosystems 
(Foster City, CA, USA) enabled first strand synthesis. 
Expression of target genes (PRMT6, CD44, MMP9, 
AR, MLL1, MLL2, MLL3, MLL4, MLL5 and SMYD3) 
was quantified using Taqman expression assays 
(Supplementary Table 1), purchased as pre-developed 
assays (Applied Biosystems) and normalized to the 
expression of GUSB (housekeeping gene).
Protein extraction and western blot analysis
Protein was extracted from whole-cell lysates using 
Kinexus Lysis Buffer with Lysis Buffer Cocktail (Kinexus 
Bioinformatics Corporation, Vancouver, British Columbia, 
Canada) and protein concentration was determined using 
BCA assay (Thermo Scientific, Waltham, MA, USA). 
Subsequently, 30 μg of total protein were separated by 
SDS-PAGE, transferred to nitrocellulose membranes and 
incubated with antibodies against PRMT6, H3R2me2a 
(1/500 Novus Biologicals, Littleton, CO), H3K4me3, PSA 
(1/1500 and 1/6000 Abcam, Cambridge, UK), AR, mTOR 
(1/1000, Cell Signaling Technology, Inc., Danvers, MA), 
p21, p27 (1/500, BD Biosciences, Franklin Lakes, NJ), 
AKT (1/500, Santa Cruz Biotechnologies Inc) and pAKT 
(1/500, Millipore Billerica, MA), as well as histone H3 
(dilution: 1:500, Abcam) and beta-actin (dilution: 1:8000, 
Sigma-Aldrich) as input controls, as appropriate. Blots 
were developed using Immun-Star™ WesternC™ Kit 
(BioRad, Hercules, CA). All experiments were performed 
in triplicate.
Viability assay
Cell viability was evaluated by MTT assay. Briefly, 
4000 and 8000 cells per well from PC-3 and LNCaP 
were seeded onto 96-well flat bottoned culture plates 
and allowed to adhere overnight. At each time point 0.5 
mg/ml of MTT reagent [3-(4, 5dimethylthiazol-2-yl)-2, 
5-diphenyl-tetrazolium bromide] was added to each 
well, and the plates were incubated in the dark for 2 
hours at 37ºC. Formazan crystals were then dissolved 
in DMSO and absorbance was read at 540 nm in a 
microplate reader (FLUOstar Omega, BMG Labtech, 
Offenburg, Germany), subtracting the background, at 
630 nm. The number of cells was calculated using the 
formula: [(OD experiment x Number of cells at day 0) / 
Mean OD at day 0]. Three replicates were performed for 
each condition, and at least 3 independent experiments 
were performed.
Apoptosis evaluation
Evaluation of apoptosis was performed using 
APOPercentage apoptosis assay kit (Biocolor Ltd., 
Belfast, Northern Ireland) according to the manufacturer’s 
instructions. PCa cells were seeded onto 96-well plates at 
the same concentrations used for MTT assay. Apoptotic 
cells were assessed upon 72 hours of cell adherence in 
a FLUOstar Omega microplate reader at 550 nm and 
the background subtracted at 620 nm. The results were 
normalized to number of viable cell obtained in the MTT 
assay according to the following formula (OD of apoptosis 
assay at day x/OD of MTT at day x). The results of the 
apoptosis assay on the silenced cells were expressed as 
the ratio of the values obtained for scramble cells (set 
as 100%). Three biological independent experiments 
were performed with methodological triplicates for each 
experiment.
Cell invasion assay
Cell invasion was determined using BD BioCoat 
Matrigel Invasion Chamber (BD Biosciences, Franklin 
Lakes, NJ, USA). Briefly, 2500 cells in 500 μL of serum-
free medium were seeded in Matrigel inserts for 48 hours, 
after which the non-invading cells were removed with 
cotton swabs from the upper side of the membrane. The 
membrane botton containing invading cells was fixed in 
methanol, washed in PBS and stained with DAPI (Vector 
Laboratories, Burlingame, CA). All the invading cells 
were counted under a fluorescent microscope. Three 
independent experiments were performed for each 
condition, and at least two experimental replicates were 
performed.
Wound-healing assay
Briefly, Sc and Sh PC-3 cells were grown to full 
confluence in 24-well plates, the medium was removed 
and scratches were performed using a 100μL tip. Cells 
were then washed with PBS and medium replaced. Scratch 
closure was analyzed under the inverted microscope 
and images were captured at different time points. The 
calculations were made according to the formula [(S 
Time zero-S Time point/S Time zero) x 100, where S = 
Distance)]. Three biological independent experiments 
were performed with methodological quadruplicates for 
each experiment.
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Statistical analysis
Multiple and pairwise comparisons were 
performed using the Kruskal-Wallis and Mann-Whitney 
U tests, respectively, both in clinical samples and in in 
vitro experiments. A receiver operator characteristic 
(ROC) curve was constructed to assess the performance 
of PRMT6 as diagnostic biomarker. Spearman 
correlation tested association between transcript 
levels of different genes. Fisher’s exact test measured 
association between prostate sample type and PRMT6 
immunoexpression.
Survival analysis was performed in TCGA dataset. 
Prognostic significance of available clinical parameters 
(pathological stage, GS, age, and serum PSA levels) was 
assessed by constructing disease-specific and disease-free 
survival curves using the Kaplan-Meier method with log-
rank test (univariate analysis). A Cox-regression model 
comprising the four variables (multivariate analysis) was 
also constructed. Disease-free survival was calculated 
from the date of radical prostatectomy to date of 
biochemical recurrence, or date of last follow-up or death 
if recurrence-free. For survival analyses purposes, all 
cases were coded according to median PMRT6 transcript 
and serum PSA levels.
Statistical significance was set at P<0.05. 
Bonferroni’s correction was applied to pairwise 
comparisons. Statistical analyses were performed using 
SPSS software, version 22.0 (IBM-SPSS Inc., Chicago, 
IL, USA).
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